TDC
MACK

Thompson Davis & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Thompson Davis & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,271
Closed -$124K – 1312
2015
Q2 		$124K Hold
1,271
– – 0.14% 169
2015
Q1 		$119K Hold
1,271
– – 0.14% 158
2014
Q4 		$113K Buy
1,271
+635
+100% +$46.3K 0.13% 162
2014
Q3 		$44K Buy
+636
New +$34K 0.06% 290

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Thompson Davis & Co's MACK Position: Q3 2015 in Review

Thompson Davis & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 1,271 shares — an estimated $124K sold.

Thompson Davis & Co first reported a position in MACK in Q3 2014 and held it in 4 quarters. The position peaked at $124K in Q2 2015. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

  • Thompson Davis & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 1,271 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $124K.
  • Thompson Davis & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
  • Thompson Davis & Co's Merrimack Pharmaceuticals, Inc. position peaked at $124K in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on Thompson Davis & Co's 13F filing for Q3 2015, filed 30 Oct 2015.